<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04417842</url>
  </required_header>
  <id_info>
    <org_study_id>V1 21APR2020</org_study_id>
    <nct_id>NCT04417842</nct_id>
  </id_info>
  <brief_title>Connect Lung Outcomes With Bronchodilator Use</brief_title>
  <acronym>CLOUD</acronym>
  <official_title>CLOUD Study: Connect Lung Outcomes With Bronchodilator Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmonary Critical Care Associates of Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pulmonary Critical Care Associates of Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the accuracy of the Respimetrix flow-volume monitoring device in measuring the&#xD;
      patient's inspiratory capacity as compared to gold-standard measurements of inspiratory&#xD;
      capacity on pulmonary function testing. Accuracy will be assessed before and after (A)&#xD;
      pulmonary function testing and before and after (B) the administration of an inhaled&#xD;
      bronchodilator medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Specific Aim #1: Compare the performance of the flow-volume test device to standard&#xD;
           pulmonary function measurements.&#xD;
&#xD;
           The investigators hypothesize that measurements of inspiratory capacity with the&#xD;
           Respimetrix test device will:&#xD;
&#xD;
           A. Accurately measure the inspiratory capacity as assessed on standard pulmonary&#xD;
           function tests, and will B. Correlate with other measures of pulmonary function&#xD;
           including spirometry (vital capacity, forced expiratory volume in 1 second) and lung&#xD;
           volumes (total lung capacity, functional residual capacity and residual volume).&#xD;
&#xD;
        2. Specific Aim #2: Examine the ability of the flow-volume test device to track changes in&#xD;
           standard pulmonary function measurements after the administration of an inhaled&#xD;
           bronchodilator.&#xD;
&#xD;
      The investigators hypothesize that the Respimetrix test device will:&#xD;
&#xD;
      A. Accurately measure changes in inspiratory capacity in response to a standard dose of a&#xD;
      short acting inhaled beta-agonist (4 puffs albuterol), B. Correlate with immediate changes in&#xD;
      pulmonary function parameters including spirometry (vital capacity, forced expiratory volume&#xD;
      in 1 second) and lung volumes (total lung capacity, functional residual capacity and residual&#xD;
      volume).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validation</measure>
    <time_frame>1 year</time_frame>
    <description>Validate the Respimetrix device as compared to pulmonary function test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validation</measure>
    <time_frame>1 year</time_frame>
    <description>Validate Forced Vital Capacity, Forced expired volume in 1 sec, Total lung capacity and residual volume</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Respimetrix flow-volume monitoring device</intervention_name>
    <description>The Respimetrix flow-volume monitoring device is being tested to validate its ability to measure Inspiratory Capacity</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        - Patients 18 years of age or older who are being seen in the pulmonary clinic including&#xD;
        Asthma and COPD patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 years of age or older who are being seen in the pulmonary clinic including&#xD;
             Asthma and Chronic Obstructive Pulmonary Disease (COPD) patients.&#xD;
&#xD;
          -  Patients must be willing and able to provide informed consent to participate in the&#xD;
             study.&#xD;
&#xD;
          -  Patients must be able to use a metered dose inhaler.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to inhaler use&#xD;
&#xD;
          -  Tracheostomy&#xD;
&#xD;
          -  Incapacitating disability that interferes with the use of the inhaler or execution of&#xD;
             the protocol&#xD;
&#xD;
          -  Unable to understand informed consent (e.g., non-English speakers)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Stuart King, BS</last_name>
    <phone>443-841-9562</phone>
    <email>sking@pccabpa.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Highfield, PhD</last_name>
    <phone>443-797-7989</phone>
    <email>dhighfield@pccabpa.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pulmonary and Critical Care Associates Of Baltimor</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21286</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart King, BA</last_name>
      <phone>4438419562</phone>
      <email>sking@pccabpa.com</email>
    </contact>
    <contact_backup>
      <last_name>Matthew ACCAO Woodson, BA</last_name>
      <phone>410-868-9600</phone>
      <email>mwoodson@pccabpa.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 2, 2020</study_first_submitted>
  <study_first_submitted_qc>June 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pulmonary Critical Care Associates of Baltimore</investigator_affiliation>
    <investigator_full_name>Alan Schwartz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Validating a device for Respimetrix, no immediate plan to share data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

